Ovarian germ cell tumor laboratory tests
|
Ovarian germ cell tumor Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ovarian germ cell tumor laboratory tests On the Web |
|
American Roentgen Ray Society Images of Ovarian germ cell tumor laboratory tests |
|
Risk calculators and risk factors for Ovarian germ cell tumor laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2] Monalisa Dmello, M.B,B.S., M.D. [3]
Overview
The tumor marker associated with ovarian germ cell tumor subtypes are as follows:
| Ovarian germ cell tumor subtype | Tumor markers expressed |
| Dysgerminoma | |
| Embryonal carcinoma | |
| Endodermal sinus tumor or yolk sac tumors | |
| Polyembryoma | |
| Teratoma |
|
| Choriocarcinoma |
Ovarian germ cell tumor Laboratory Findings
An elevated concentration a-fetoprotein (AFP) and b-human chorionic gonadotrophin (b-hCG) are diagnostic of malignant ovarian germ cell tumors.[1]
The tumor marker associated with ovarian germ cell tumor subtypes are as follows:[2]
| Ovarian germ cell tumor subtype | Tumor markers expressed |
| Dysgerminoma | |
| Embryonal carcinoma | |
| Endodermal sinus tumor or yolk sac tumors | |
| Polyembryoma | |
| Teratoma |
|
| Choriocarcinoma |
Mature teratoma
- Mature teratoma is associated with increased level of CA 19-9. [3]
- There is a report suggesting a role for increased levels of CA-125 and AFP tumor markers in differentiating the immature teratoma and mature teratoma.[4]
Immature teratoma
Dysgerminoma
- Pure dysgerminoma, usually secret no hormones. However, 5% of tumors are capable of producing B-hCG.[6]
- Multinucleated syncytiotrophoblastic giant cells, in the dysgerminoma, produce B-hCG.
- LDH and ALK-P may be elevated nonspecifically.
Embryonal carcinoma
- They are capable of producing alpha-fetoprotein or human chorionic gonadotropin.[7]
Endodermal sinus tumor
- Yolk sac tumor is associated with increased level of AFP.[8]
Polyembryoma
Non-gestational choriocarcinoma
- They can produce human chorionic gonadotropin.[7]
References
- ↑ Pectasides, D.; Pectasides, E.; Kassanos, D. (2008). "Germ cell tumors of the ovary". Cancer Treatment Reviews. 34 (5): 427–441. doi:10.1016/j.ctrv.2008.02.002. ISSN 0305-7372.
- ↑ Ovary: Germ cell tumors. http://atlasgeneticsoncology.org/Tumors/OvarianGermCellID5067.html. URL Accessed on November 10, 2015
- ↑ Yayla Abide, Çiğdem; Bostancı Ergen, Evrim (2018). "Retrospective analysis of mature cystic teratomas in a single center and review of the literature". Journal of Turkish Society of Obstetric and Gynecology. 15 (2): 95–98. doi:10.4274/tjod.86244. ISSN 1307-699X.
- ↑ Chen C, Li JD, Huang H, Feng YL, Wang LH, Chen L (January 2008). "[Diagnostic value of multiple tumor marker detection for mature and immature teratoma of the ovary]". Ai Zheng (in Chinese). 27 (1): 92–5. PMID 18184473.
- ↑ Gershenson, David M. (2007). "Management of Ovarian Germ Cell Tumors". Journal of Clinical Oncology. 25 (20): 2938–2943. doi:10.1200/JCO.2007.10.8738. ISSN 0732-183X.
- ↑ Shaaban, Akram M.; Rezvani, Maryam; Elsayes, Khaled M.; Baskin, Henry; Mourad, Amr; Foster, Bryan R.; Jarboe, Elke A.; Menias, Christine O. (2014). "Ovarian Malignant Germ Cell Tumors: Cellular Classification and Clinical and Imaging Features". RadioGraphics. 34 (3): 777–801. doi:10.1148/rg.343130067. ISSN 0271-5333.
- ↑ 7.0 7.1 Chen, Vivien W.; Ruiz, Bernardo; Killeen, Jeffrey L.; Cot�, Timothy R.; Wu, Xiao Cheng; Correa, Catherine N.; Howe, Holly L. (2003). "Pathology and classification of ovarian tumors". Cancer. 97 (S10): 2631–2642. doi:10.1002/cncr.11345. ISSN 0008-543X. replacement character in
|last4=at position 4 (help) - ↑ Stein, Erica B.; Wasnik, Ashish P.; Sciallis, Andrew P.; Kamaya, Aya; Maturen, Katherine E. (2017). "MR Imaging–Pathologic Correlation in Ovarian Cancer". Magnetic Resonance Imaging Clinics of North America. 25 (3): 545–562. doi:10.1016/j.mric.2017.03.004. ISSN 1064-9689.
- ↑ Low, Jeffrey J.H.; Ilancheran, Arunachalam; Ng, Joseph S. (2012). "Malignant ovarian germ-cell tumours". Best Practice & Research Clinical Obstetrics & Gynaecology. 26 (3): 347–355. doi:10.1016/j.bpobgyn.2012.01.002. ISSN 1521-6934.